BarbieriCE, BacaSC, LawrenceMS, et al.Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 2012; 44(6):685–689; doi: 10.1038/ng.2279
2.
BrooksJD, WeinsteinM, LinX, et al.CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 1998; 7(6):531–536.
3.
BussemakersMJ, van BokhovenA, VerhaeghGW, et al.DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res, 1999; 59(23):5975–5979; https://pubmed.ncbi.nlm.nih.gov/10606244/
4.
CamachoDM, CollinsKM, PowersRK, et al.Next-generation machine learning for biological networks. Cell, 2018; 173(7):1581–1592; doi: 10.1016/j.cell.2018.05.015
5.
CarlssonS V. and Roobol MJ. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Curr Opin Urol, 2017; 27(3):198–204; doi: 10.1097/MOU.0000000000000382
6.
CucchiaraV, CooperbergMR, Dall'EraM, et al.Genomic markers in prostate cancer decision making. Eur Urol, 2018; 73(4):572–582; doi: 10.1016/j.eururo.2017.10.036
7.
FerroM, UngaroP, CimminoA, et al.Epigenetic signature: A new player as predictor of clinically significant prostate cancer (PCa) in patients on active surveillance (AS). Int J Mol Sci, 2017; 18(6); doi: 10.3390/IJMS18061146
8.
HaeseA, TrooskensG, SteyaertS, et al.Multicenter optimization and validation of a 2-gene MRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy. J Urol, 2019; 202(2):256–262; doi: 10.1097/JU.0000000000000293
9.
HamzehO, AlkhateebA, ZhengJ, et al.Prediction of tumor location in prostate cancer tissue using a machine learning system on gene expression data. BMC Bioinformatics, 2020; 21(Suppl 2); doi: 10.1186/s12859-020-3345-9
10.
HamzehO, AlkhateebA, ZhengJZ, et al.A hierarchical machine learning model to discover gleason grade-specific biomarkers in prostate cancer. Diagnostics, 2019; 9(4); doi: 10.3390/diagnostics9040219
11.
HesselsD, Klein GunnewiekJMT, Van OortI, et al.DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol, 2003; 44(1):8–16; doi: 10.1016/S0302-2838(03)00201-X
LaxmanB, TomlinsSA, MehraR, et al.Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia, 2006; 8(10):885–888; doi: 10.1593/neo.06625
14.
LeytenGHJM, HesselsD, SmitFP, et al.Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res, 2015; 21(13):3061–3070; doi: 10.1158/1078-0432.CCR-14-3334
15.
MaX, GuoJ, LiuK, et al.Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Mol Cancer, 2020; 19(1); doi: 10.1186/s12943-020-01264-9
NaganoK, YamashitaT, InoueM, et al.Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochem Biophys Res Commun, 2014; 450(1):545–549; doi: 10.1016/j.bbrc.2014.06.007
18.
PartinAW, Van NesteL, KleinEA, et al.Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol, 2014; 192(4):1081–1087; doi: 10.1016/j.juro.2014.04.013
19.
RawlaP. Epidemiology of prostate cancer. World J Oncol, 2019; 10(2):63–89; doi: 10.14740/wjon1191
20.
StewartGD, Van NesteL, DelvenneP, et al.Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study. J Urol, 2013; 189(3):1110–1116; doi: 10.1016/j.juro.2012.08.219
21.
TangZ, LiC, KangB, et al.GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017; 45(W1):W98–W102; doi: 10.1093/nar/gkx247
22.
TǎtaruOS, MarthaO, CrocettoF, et al.Fascin-1 and its role as a serological marker in prostate cancer: A prospective case-control study. Future Sci OA, 2021; 7(9); doi: 10.2144/FSOA-2021-0051
23.
TătaruOS, VartolomeiMD, RassweilerJJ, et al.Artificial intelligence and machine learning in prostate cancer patient management-current trends and future perspectives. Diagnostics (Basel), 2021; 11(2):354; doi: 10.3390/DIAGNOSTICS11020354
24.
TomlinsSA, BjartellA, ChinnaiyanAM, et al.ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol, 2009; 56(2):275–286; doi: 10.1016/j.eururo.2009.04.036
25.
WangH, WuR, YuL, et al.SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression. Oncol Rep, 2012; 28(4):1468–1474; doi: 10.3892/or.2012.1917
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
